BOSTON, April 22, 2025--(BUSINESS WIRE)--Cycle Pharmaceuticals (Cycle) has launched Cycle Vita PKU, an AI-powered app to help patients with PKU manage every aspect of their treatment plan.

Cycle Pharmaceuticals Limited (Cycle) announced today the launch of VENXXIVA (tiopronin) Delayed-Release Tablets, for the treatment of cystinuria, approved by the US Food and Drug Administration ...

Cycle Pharmaceuticals, Inc. (Cycle) announces today completion of the acquisition of Banner Life Sciences, LLC (Banner) which includes its BAFIERTAM (monomethyl fumarate) product for the treatment ...

One of the most strategic moves a pharmaceutical company can make is to establish an evidence generation plan (EGP) early in the asset life cycle—ideally around phase one. While much attention ...

A woman raped at knifepoint in the Cambridgepark office complex in May sued the ... of the building at 125 Cambridgepark Drive, Cambridge,” the lawyers wrote. They added that there are ...

WCVB NEWSCENTER FIVE. SARAH. THANK YOU. A MOTHER HAS FILED A LAWSUIT CLAIMING SHE WAS RAPED AT KNIFEPOINT IN A CAMBRIDGE OFFICE BUILDING. THE 46 YEAR OLD SAYS IT HAPPENED WHILE SHE WAS WORKING AT ...

(Reuters) -Vanda Pharmaceuticals on Monday rejected UK-based Cycle Pharmaceuticals' second takeover proposal, which values the drugmaker at $8 per share despite a drop in Vanda (NASDAQ:VNDA)'s ...

WASHINGTON - Vanda (NASDAQ:VNDA) Pharmaceuticals Inc. (NASDAQ: VNDA), a global biopharmaceutical company, has declined a second acquisition proposal from Cycle Group Holdings Ltd., maintaining that ...

2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it received a second unsolicited, non-binding proposal from Cycle Group Holdings Ltd ...

The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s Cycle Pharmaceuticals to acquire the Washington D.C.-based company.